Please assess the completion status of the following clinical trial:

Trial Title: Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with metastatic or unresectable stage IIIb/c of IV melanoma for whom treatment with pembrolizumab is indicated and who have at least one cutaneous, subcutaneous tumor or palpable lymph node amenable to intratumoral injection.~* At least one tumor must qualify to be an index lesion for modified WHO criteria.~* Subjects must have adequate hematologic, hepatic and renal function.~* ECOG performance status of 0 or 1.~* Anticipated lifespan greater than 12 weeks~Exclusion Criteria:~* Ocular primary tumors.~* Presence of any central nervous system tumor that has not been stable for at least 4 weeks off corticosteroids.~* Tumors lying in mucosal regions or close to an airway, major blood vessel or spinal cord.~* Subjects with active, known or suspected autoimmune or immunosuppressive disease.~* Subjects previously treated with CVA21.~* Subjects requiring systemic treatment with corticosteroids or other immunosuppressive medications within 14 days prior to the first treatment.~* Subject has received chemotherapy within the last 4 weeks prior to first treatment.~* Clinically significant cardiovascular disease.~* Females of childbearing potential must have negative serum or urine pregnancy test.~* Subjects requiring or using other investigational agents while on treatment in this trial.~* History of other malignancy within the last 3 years (with exceptions).~* Active infection requiring systemic therapy.~* Known history of HIV disease, active hepatitis B or hepatitis C.~* History or evidence of other clinically significant disorders that would pose a risk to subject safety.~* Inability to give informed consent and comply with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CAVATAK and pembrolizumab (Type: EXPERIMENTAL): Intratumoral CAVATAK administration on trial days 1, 3, 5 and 8 and at 3-weekly intervals up to a maximum of 19 total with intravenous pembrolizumab (2 mg/kg solution) starting on day 8 and continuing every 3 weeks, up to 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).